High-affinity interaction of sartans with H+/peptide transporters

Drug Metabolism and Disposition

Volumn 37, Issue 1, 2009, Pages 143-149

  Knütter, Ilka ^a   Kottra, Gabor ^b   Fischer, Wiebke ^a   Daniel, Hannelore ^b   Brandsch, Matthias ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; CEFADROXIL; EPROSARTAN; GLYCYLSARCOSINE; IRBESARTAN; LOSARTAN; PEPTIDE TRANSPORTER 1; PEPTIDE TRANSPORTER 2; PROTON; VALSARTAN;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG INHIBITION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TRANSPORT; DRUG UPTAKE; HEART FAILURE; HUMAN; HUMAN CELL; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; XENOPUS LAEVIS;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CACO-2 CELLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HELA CELLS; HUMANS; PROTEIN BINDING; RATS; SPECTROPHOTOMETRY, ULTRAVIOLET; SYMPORTERS; XENOPUS LAEVIS;

XENOPUS LAEVIS;

EID: 58149478531     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.022418     Document Type: Article

References (20)

1. Brandsch M, Knütter I, and Bosse-Doenecke E (2008) Pharmaceutical and pharmacological importance of peptide transporters. J Pharm Pharmacol 60:543-585.
2. 50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
3. Daniel H and Kottra G (2004) The proton oligopeptide cotransporter family SLC15 in physiology and pharmacology. Pflugers Arch 447:610-618.
4. 1Rezeptorantagonisten: Gibt es Unterschiede? J Kardiol 6:488-494.
5. 3H]losartan across isolated perfused rabbit proximal tubule. J Pharmacol Exp Ther 290:38-42.
6. Ekins S, Johnston JS, Bahadduri P, D'Souza VM, Ray A, Chang C, and Swaan PW (2005) In vitro and pharmacophore-based discovery of novel hPEPTl inhibitors. Pharm Res 22:512-517.
7. Jack D (2000) The sartans are coming! Drug News Perspect 13:121-124.
8. Jugdutt BL (2006) Valsartan in the treatment of heart attack survivors. Vasc Health Risk Manag 2:125-138.
9. Knütter L Hartrodt B, Theis S, Foltz M, Rastetter M, Daniel H, Neubert K, and Brandsch M (2004) Analysis of the transport properties of side chain modified dipeptides at the mammalian peptide transporter PEPT1. Eur J Pharm Sci 21:61-67.
10. +/peptide transporters revisited. J Pharmacol Exp Ther 327: in press.
11. +/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm 59:17-24.
12. Metzner L, Natho K, Zebisch K, Dorn M, Bosse-Doenecke E, Ganapathy V, and Brandsch M (2008) Mutational analysis of hisrtdine residues in the human proton-coupled amino acid transporter PAT1. Biochim Biophys Acta 1778:1042-1050.
13. +/peptide cotranspoilers PEPT1 and PEPT2 in intestinal and renal epithelial cells. Eur J Biochem 271:2012-2017.
14. Perico N and Remuzzi G (1998) Angiotensin LI receptor antagonists and treatment of hypertension and renal disease. Curr Opin Nephrol Hypertens 7:571-578.
15. Ramasubbu K, Mann DL, and Deswal A (2007) Anti-angiotensin therapy: new perspectives. Cardiol Clin 25:573-580; vi-vii.
16. +/peptide transporter PEPT2. J Biol Chem 277:7287-7292.
17. Wang J, Ho L, Chen L, Zhao Z, Zhao W, Qian X, Humala N, Seror I, Bartholomew S, Rosendorff C, et al. (2007) Valsartan lowers brain β-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest 117:3393-3402.
18. 1- receptor. Drug Metab Dispos 35:2166-2176.
19. 1-receptor, in humans. Drug Metab Dispos 34:1247-1254.
20. Young AM, Audus KL, Proudfoot J, and Yazdanian M (2006) Tetrazole compounds: the effect of structure and pH on Caco-2 cell permeability. J Pharm Sci 95:717-725.